Press Release ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection ClearNote Health May 27, 2026
Press Release ClearNote Health to Present Early Detection Validation Data for Avantect® Pancreatic Cancer Test at 2026 ASCO Annual Meeting ClearNote Health May 22, 2026
Press Release ClearNote Health to Present Industry-Leading Early Detection Data for Avantect® Pancreatic Cancer Test at Digestive Disease Week 2026 ClearNote Health May 8, 2026
Press Release ClearNote Health’s Avantect® Test Selected for World’s Largest Study of Pancreatic Cancer Detection in High-Risk Patient Population ClearNote Health December 18, 2024
Press Release Avantect Pancreatic Cancer Test Cost-Effective When Used as a Surveillance Tool in High-Risk Patients Newly Diagnosed with Diabetes ClearNote Health October 31, 2024
Press Release Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services ClearNote Health September 26, 2024
Press Release New Data Show ClearNote Health’s Epigenomic Platform Provides a Novel Tissue-Free, Liquid Biopsy-Based Approach to Identify Potential Predictive Biomarker Candidates to Radioligand Therapy Response in Patients With Pancreatic Neuroendocrine Tumors ClearNote Health March 26, 2024
Press Release Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology ClearNote Health January 30, 2024
